Inflexion Outlines Rosemont Investment And Eyes More Generics Deals

June Deal Was Inflexion’s First In Generics Space

 
• By Dean Rudge

In an exclusive interview with Generics Bulletin, Inflexion’s Ben Long reveals his ambitions for newly-acquired UK-based liquids generics specialist Rosemont Pharmaceuticals, including to drive investment in R&D and expand the company’s international footprint.

Interview_2020_2
Thousands of generics remain unavailable in a liquid form, according to Rosemont's new owner Inflexion • Source: Shutterstock

Inflexion, the UK-based private equity that acquired liquid generics specialist Rosemont Pharmaceuticals from Perrigo earlier this year, has underlined its appetite for “kickstarting and quite significantly increasing the investment in licensing and internal research and development at the company,” as it revealed it would “absolutely love to make further investments” in the generics space.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products